Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Morgan Stanley B.V. - six months interim report and financial statements for the period ended 30 June 2026Companies: Morgan StanleyMorgan Stanley B.V. hereby announces that the interim report and financial statements for the six months period ended 30 June 2026 as expressed in article 5.25d of the Act on Financial Supervision ("Wet op het financieel toezicht") has been made...
- ŌURAŌURA Announces Launch of Initial Public OfferingCompanies: Jefferies Financial GroupMorgan StanleySAN FRANCISCO, September 21, 2026--ŌURA, a leading health intelligence platform and maker of the world’s smallest smart ring, today announced that it has launched its initial public offering of 50,000,000 shares of its common stock. The offering consists of 13,500,000 shares offered by Oura and 36,500,000 shares offered by certain of Oura’s existing stockholders. In addition, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 7,500,000 share
- Certain Morgan Stanley Closed-End Funds Declare Quarterly DividendsCompanies: Morgan StanleyNEW YORK, September 18, 2026--Each of the Morgan Stanley closed-end funds listed below (the "Funds") today declared the following dividends.
- Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common StockCompanies: Morgan StanleyCAMBRIDGE, Mass., August 20, 2026--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
- Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSsCompanies: Jefferies Financial GroupMorgan StanleyLONDON, August 14, 2026--Silence Therapeutics plc, (Nasdaq: SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which incl
- Morgan StanleyMorgan Stanley Declares Dividends on Its Preferred StockCompanies: Morgan StanleyNEW YORK, August 14, 2026--Morgan Stanley today declared a regular dividend on the outstanding shares of each of the following preferred stock issues: